$BYSI

BeyondSpring (BYSI) reported Q3 2026 net income of $50.5M, driven by a $53.7M gain from selling subsidiary interests, while continuing operations had a $2.1M net loss. The company had no revenue and a $2.1M operating loss. FDA granted Fast Track designation to Plinabulin plus docetaxel for NSCLC treatment. BeyondSpring sold its stake in Bulin to Biolin, which will support China-based enrollment in the DUBLIN-4 trial.

BeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update FDA Fast Track Designation for Plinabulin plus docetaxel marks key regulatory milestone in DUBLIN-4 study population of Post-ICI Non-Squamous NSCLC with no actionable genomic alte

BeyondSpring reported a Q3 GAAP EPS of -$0.04. The company's cash and short-term investments decreased to $0.6 million from $4.0 million over the past year.

BeyondSpring (BYSI) received FDA Fast Track designation for plinabulin plus docetaxel in non-squamous NSCLC. The company expects a Biolin transaction to fund half of the DUBLIN-4 trial's 442 patients, with an interim analysis planned at 221 PFS events.

BeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. (a) BeyondSpring Inc. (the “Company”) held its 2026 annual meeting of shareholders on October 13, 2026. A total of 20,905,921 of the Company’s ordinary shares were present or represented by proxy at the meeting, repr

BeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On September 28, 2026, BeyondSpring Inc. (“BYSI” or the “Company”) entered into a Share Purchase and Collaboration Agreement (the “Agreement”) with Dalian Wanchunbulin Pharmaceuticals Ltd. (“Bulin”), a

BeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis FDA Fast Track designation represents an important regulatory milestone

BeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibito

BeyondSpring Inc. (NASDAQ: BYSI) announced a leadership transition effective July 1, 2026. Dr. Lan Huang will remain Chairman; Dr. Jiangwen (Jen) Majeti becomes Vice Chairman; Min Qiu is appointed CEO to execute the confirmatory DUBLIN-4 Phase 3 trial of Plinabulin plus docetaxel; and Na Li becomes CFO to strengthen the company’s financial position and capital markets engagement.

BeyondSpring Inc. (BYSI) insiders Lan Huang and Linqing Jia each reported beneficial ownership of 5,787,906 shares, representing 14.1% of the company's outstanding shares as of March 31, 2026. This disclosure was made in an Amendment No. 9 to a Schedule 13G/A filing, detailing ownership through various entities, trusts, and proxies, and clarifying shared voting and dispositive powers. The filing also revealed recent intra-family trust transfers of 260,582 and 253,465 shares.